Twist Bioscience targets $442M-$447M FY2026 revenue while staying on track for Q4 FY2026 adjusted EBITDA breakeven
ORIGINAL SOURCE →via Seeking Alpha
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] A century since Dreyfus's wrongful conviction, a family member is promoted in the IDF
- [CONFLICT] Türkiye ve Ermenistan arasında ilk somut protokol: Ani Köprüsü restorasyonu
- [CONFLICT] Police disperse hundreds of civilians from Mount Meron attempting to light fires for Lag Ba'omer
- [CONFLICT] Maliye'den kayıt dışına sıkı takip